SXTP
60 Degrees Pharma Inc
NASDAQ · Pharmaceuticals
$4.16
+0.31 (+8.05%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 976.3K | 862.6K | 990.0K |
| Net Income | 166.4K | 198.9K | 215.4K |
| EPS | — | — | — |
| Profit Margin | 17.1% | 23.1% | 21.8% |
| Rev Growth | +8.4% | -6.7% | +4.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.74M | 1.77M | 1.68M |
| Total Equity | 3.07M | 3.39M | 2.90M |
| D/E Ratio | 0.57 | 0.52 | 0.58 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 375.1K | 334.7K | 417.4K |
| Free Cash Flow | 225.2K | 224.8K | 208.8K |